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Toward individual prognosis of IgA nephropathy. The individual
prognosis of adult IgA nephropathy patients was studied using the
proportional hazards model for the time from biopsy until endstage
renal disease. After selection of the most relevant prognostic factors,
the 75 patients were stratified with respect to hypertension and its
treatment. In these strata, individual prognosis was based on (1) the
initial age-adjusted glomerular filtration rate, (2) the initial proteinuria,
(3) the presence/absence of gross hematuria, and (4) the presence/ab-
sence of microscopic hematuria, Using the scores of a patient on these
variables, the probability of surviving any given period of time can be
estimated either graphically or by calculation. Prediction is feasible up
to about 10 years. Attention has been given to supply all relevant
estimates with confidence limits. For each patient the estimated 5-year
survival probability as predicted by the model was compared with the
actual outcome.
Primary IgA nephropathy (IGAN) is characterized by prom-
inent mesangial IgA deposits in the absence of histological signs
of other primary glomerular diseases and without clinical signs
of Henoch-Schönlein purpura (HSP), systemic lupus
erythematosus (SLE), or cirrhosis of the liver [1, 2]. The
diagnosis of IGAN is frequently made and its incidence is
reported to be 8 to 50% in patients who are biopsied for a
suspected glomerulonephritis [1—3]. In a specially tested popu-
lation of military recruits in Malaysia, the prevalence of clini-
cally latent IGAN was reported to be between 0.8 and 11.7%
[4]. In a secluded region of France the minimum prevalence in
a total population not closely investigated was 0.2% [5].
Despite worldwide extensive research, the pathogenesis of
IGAN is still uncertain and, consequently, a specific therapy is
unknown [61. Six to nineteen percent of the patients in different
groups have been reported to progress to endstage renal disease
[2, 3, 7—101. Actuarial kidney survival of IGAN patients was
estimated to be 76% after 10 years and 47% after 20 years [101.
Several factors are known to influence the prognosis of
patient groups (see Table 1). The prognosis for an individual
patient, however, requires that the interdependence and the
relative "weights" of these factors are estimated. In this paper
we examine the feasibility of such an individual prognosis by
use of the proportional hazards model as introduced by Cox
[11].
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Method
The Groningen University Hospital is a referral hospital
covering the northern 3.5 of the 11 Dutch provinces (population
2,000,000). According to the Department of Pathology ar-
chives, between July 1, 1967, and January 1, 1983, 75 adult
patients of the Department of Nephrology were diagnosed as
having IGAN. Sufficient clinical intake data and follow-up data
were available for all these patients. The inclusion criteria were:
(1) prominent mesangial IgA-deposits; (2) no clinical signs of
SLE, HSP, or cirrhosis of the liver; (3) no morphological
evidence of other types of primary glomerular disease; (4) age at
biopsy  12 years; (5) all patients concerned were biopsied
before transplantation or dialysis was necessary. Moreover, all
biopsy specimens of patients with macroscopic hematuria were
taken more than 6 weeks after the last attack.
The median values of three to ten prebiopsy measurements of
(1) microscopic hematuria (RBC/hpt), (2) proteinuria (g pro-
teinl24 hr; biuret reaction with albumin standard), and (3) 24-hr
creatinine clearance (mllmin) were obtained from the hospital
records. Hypertension was assumed to be present if diastolic
blood pressure exceeded 97 mm Hg or if the patient used
antihypertensive drugs before the biopsy. If diastolic blood
pressure decreased below 97 mm Hg within 3 months after
biopsy and remained below this limit, hypertension was con-
sidered to be treated adequately. The first manifestation of the
disease was defined as either the date of the first bout of
macroscopic hematuria or the date of objective laboratory
evidence of renal disease [proteinuria, hematuria, or decrease
of glomerular filtration rate (GFR)].
Follow-up continued to August 1, 1983. Only three of the 75
patients were dropped from the follow-up before the closing
date (two patients emigrated; one died due to myocardial
infarction with a normal renal function). The median period of
follow-up was 8.0 years after the first manifestation and 5.3
years after biopsy. Twenty-five percent of the patients had been
in the study for more than 13 years after the first manifestations
(and for more than 7.5 years after the biopsy). All retrievable
renal biopsy specimen data were reclassified by one pathologist
without knowledge of patient identity. A seiniquantitative score
was established for the following morphological characteristics:
mesangial widening, mesangial sclerosis, global sclerosis,
intracapillary proliferation, extracapillary proliferation, mesan-
gial proliferation, adhesions, interstitial infiltration, tubular
atrophy, and vessel abnormalities.
Survival analysis, for the whole group of IGAN patients and
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Table 1. Factors previously known to lead to an unfavorable
prognosis for patient groups with IgA nephropathy [2, 7—10, 22, 251
Clinical data Histological data
Proteinuna Global sclerosis
Hypertension Tubulo-interstitial degeneration
High age at onset Interstitial Ig-deposits
Initially low GFR
Absence of macroscopical hematuria
Male sex
for various subgroups, was performed on a DEC 10 computer
using the program BMDP1L in the statistical package BMDP.
For each group Kaplan-Meier estimates and corresponding
standard errors were calculated. Univariate differences in sur-
vival between disjoint subpopulations were tested using
Gehan's generalization of Wilcoxon's two sample statistic
[12—141.
Our study on the individual prognosis of IGAN is based on
the proportional hazards model [11—13, 15—21]. The basic as-
sumption of this model is expressed by:
A(tz) A(tIO) exp (b1z1 + ... + bkzk) (1)
where t denotes time which, for each patient separately, is
measured from biopsy onward; z = (z1, ..., z) are the scores of
the k risk factors for the patient under consideration as mea-
sured at the time of biopsy; A(tlz) is the cumulative hazard rate
at moment t for a patient with risk factor scores z1, ..., zk; A(tIO)
is the "base line" cumulative hazard function for a patient,
whose risk factor scores are all equal to zero; b1 bk are the
regression coefficients, which determine the relative impor-
tance of the risk factors. If b1 = 0, the corresponding risk factor
does not have an independent influence amid the joint action of
the other risk factors. If b is greater than 0, an increase of the
score zj for the corresponding risk factor will have an unfavor-
able influence on survival (the opposite holds true if b <0).
For the actual calculations the program BMDP2L [121 was
used. Maximizing the so-called "partial likelihood function"
L (b1 bk), this program calculates estimates 6 6k of the
regression coefficients and an estimate of the corresponding
covariance matrix. Furthermore, it yields an estimate of A (tO).
The calculated value of 6 depends on an arbitrary choice of
units in the corresponding z. If units in z are twice as small, the
value of z doubles, and, therefore, the computer calculates a
new 6 value half as large as the old one. Therefore, the mere
value of 6 does not precisely reflect the importance of a risk
factor.
There are several better ways to look at the relative impor-
tance of the various risk factors in predicting the survival time:
A1. If the proportional hazards model is appropriate, then the
estimate 6 is approximately normally distributed with expecta-
tion bj and standard deviation sE(63). The statistic f = 61IsE(6)
can be used to test the null-hypothesis that b = 0 (one rejects
this hypothesis if I > 1.96; a = 0.05). Accordingly, gives
an impression of the importance of risk factor j.
A2. Adding a new covariate with score zk+I yields a new
value for the partial likelihood function (and new regression
coefficients b1', ..., b'k+l). The influence of this new covariate is
asymptotically "significant" if it causes a significant increase of
the partial likelihood function. This is tested by means of a x2
statistic, which should almost be equal to the square of Pk+1 as
considered under A1.
B. Considering the N 75 patients as a sample from a larger
population, the risk factors can be seen as random variables,
which will be denoted by the capitals Z1, ..., Zk; SD(Z3) is the
estimated SD of Z3. Asymptotically, the "predictive force" of
risk factor 1 can be considered to be larger than that of risk
factor 2 if:
6 I X SD(Z1)> I 6 I X SD(Z2) (2)
To facilitate comparison of the influence of continuous versus
dichotomous covariates, one can use the statistic = exp
(6.D) where D = 2 sD(Z) for a continuous covariate, and D =
1 for a dichotomous factor. (The values of are given in Tables
5, 6, and 7.)
Note that these criteria concentrate on different issues.
Criteria A1 and A2 focus on the question of whether the data
provide sufficient evidence that the estimated coefficient b3 of a
certain risk factor differs from zero. Criterion B is related more
directly to the question of whether one risk factor is likely to be
a more important predictor than another factor; a drawback,
however, is that it neglects the standard errors in the regression
coefficients 6.
The probability of survival (tIz) for a given patient with
scores z = (z1, ..., Z) is given by
S(tlz) = exp [— A(tlz)] (3)
and can be estimated by plugging into formulas 1 and 3 the
scores z1, ..., Zk plus the estimates 6 and A(tIO) as calculated by
the BMDP program. (A graphical solution centering around
Figure 2 is explained in the Appendix.)
Theory for estimating the asymptotic SD of A(tlz) and S(tlz)
has been recently developed [16, 20, 21, 26]. As no implemen-
tation in a general computer package was available, a specially
devised program in FORTRAN was used for the necessary
calculations.
Results
In Table 2 patient data just prior to biopsy are summarized.
These findings are comparable to those published elsewhere
[1—3, 22, 23]. Also, the morphological features of our patients
are similar to those described in literature [1—3, 22, 231 (see
Table 3).
Kaplan-Meier estimates for kidney survival are represented
in Figure 1. Curve A refers to the kidney survival time from first
manifestation onward; 10 years after the first manifestation of
IGAN, 84% of the patients are expected to be living without
dialysis, while 10 years later this fraction amounts to 67%.
Curve B depicts survival from biopsy until dialysis. Although
curve B is influenced by various selection mechanisms (referral
patterns and indications for biopsy), we restricted the attention
to survival from biopsy onward because (1) the diagnosis of
IGAN is not possible without biopsy; (2) all clinical and
morphological data were collected just before or during biopsy;
(3) the prognostic importance of the individual risk factors in
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Table 2. Clinical characteristics of IgA nephropathy patients (N = 75)5
Insf —
Widened mesangium 4 16 8 27 7
Mesangial sclerosis 4 20 9 21 8
Global sclerosis 3 30 14 10 5
Intracapillary proliferation 4 48 4 5 1
Extracapillary proliferation 4 53 1 2 2
Mesangial proliferation 4 47 6 5 0
Adhesions 5 37 3 16 1
Interstitial infiltration 0 37 4 19 2
Tubular atrophy 1 18 13 15 15
Vessel abnormalities 2 37 3 12 8
univariate survival analysis was roughly the same for "survival
from first manifestation to dialysis" (results not shown) as for
"survival from biopsy to dialysis."
The results of the univariate analyses are summarized in
Univariate
Variable values effect
1. Macroscopic hematuria present *
2. Microscopic hematuria present — 0
3. Initial proteinuria> 2 g/24 hr ***
4. Initial creatinine clearance < 80 mllmin 'KI"K
5. Hypertension present I',l'
6. Age, 25 years — 0
7. Interstitial infiltration ** i
8. Tubular atrophy **
9. Global sclerosis **
10. Mesangial widening 0
11. Mesangial sclerosis — 0
12. Mesangial proliferation — 0
13. Intracapillary proliferation — 0
14. Extracapillary proliferation — 0
15. Adhesions — 0
16. Vascular abnormalities — 0
Table 4. When considered individually, 7 out of 16 potential risk
factors appeared to have a statistically significant effect on the
prognosis of patient groups (that is, the prognosis of the patient
subset for whom such a risk factor is present differs from that of
the patient subset without this risk factor). As already men-
tioned in the introduction, the univariate analysis is not very
suitable for the prognosis of one single patient because it is not
obvious from Table 4 how a combination of risk factors has to
be considered. For that purpose the proportional hazards model
was applied. However, prior to this multiple regression analy-
sis, a selection had to be made from the 16 risk factors in Table
4 to avoid excessive multidimensionality. We decided not to use
the morphological variables in the proportional hazards model
initially, because such information was only available for 62 of
the 75 patients.
In the first round of multiple regression analysis seven factors
were considered: factors I through 6 of Table 4 and, addition-
ally, a time factor T indicating the date of biopsy and therefore
approximately the start of treatment. This last factor was
included to detect a global time trend between 1967 and 1983.
Percentage Range Median Units
Females 17 Age first manifestation 6—74 24 years
Noncaucasians 15 Creatinine clearancec 8—167 94 mI/mm
Bouts of macroscopic hematuria 46 Microscopic hematuriac 0—50 15 RBC/hpf
Proteinuria < 0.5 g/24 hr 26 Proteinuriac 0—8 2 g/day
Hypertension 37 Serum 1gM 118—614 269 mg %
Anamnestic nephritis in family 11
In ESRD before 01-08-83 19
In remission before 010883b 23
a All biopsies (and thus, all measurements) were performed at least 6 weeks after the last bout of macroscopic hematuria.
b Proteinuria <0.5 g/24 hr, normal urinary sediment and stable GFR (at least during the last year of follow-up, on 2 measurements).
c The median value of 3 to 10 measurements just before biopsy is represented.
d was measured in August 1982 (N = 44 patients) by rate-nephelometry.
Table 3. Morphological characteristics of IgA nephropathy patients(N = 62)
Table 4. Univariate analysis: influence of single (dichotomized)
factors on the survival of groups of IgA nephropathy patients
80
60
40
Abbreviation: Insf, insufficient amount of tissue samples available.
Semiquantitative scores were achieved by one pathologist without
his knowledge of patient identity (—, absent; + +, very prominent).
A
0 50 100 150 200 250 300 350
Time, months
Fig. 1. Estimated overall kidney survIval of adult primary IgA nephrop-
aMy. Curve A represents the estimated kidney survival time from first
manifestation onward; curve B represents the estimated kidney survival
time from biopsy onward. Numbers in parentheses are patients still at
risk.
Symbols are: —, 0.05 P; ', 0.01  P < 0.05; **, 0.001 P <0.01;, P < 0.001; , patients with this characteristic have a better
prognosis; 0, no effect on prognosis; , patients with this characteristic
have a worse prognosis.
The Gehan statistic was used to determine P values.
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Table 5. Multiple regression analysis according to the proportional hazards model (first round)a
Covariable Scale 6 6ISE(6) exp (6D)
Hypertension Present = 1; not present = 0 1.6 1.7 5.2
Macroscopic hematuria Present = 1; not present = 0 —1.8 —1.7 6.0—'
Microscopic hematuria (30 RBCIhpf) Present = 1; not present = 0 1.5 1.8 4.3
Initial GFR (GFR (mI/mm) 100)150 —1.9 —2.8 14.9-'
Proteinuria (Prot (g/24 hr) — 2)/2 1.1 2.3 7.3
Age at biopsy (Age (yr) — 30)/10 —0.84 —1.9 8.7'
T (time of biopsy) (Date of biopsy-1975)/5 —0.25 —0.6 1.5'
Abbreviations are: 6, an estimate of the regression coefficient for the corresponding covariable (see Eq. (1); b/sE(b), determines the strength of
the evidence that b 0; D equals 2 times the estimated SD of Z if Z is a continuous covariable, and D = 1 if Z is a dichotomous covariable; exp
(6D) determines the "predictive force" of a certain risk factor by estimating the relative risk (exp(6D)) for patients with score Z + D with respect
to patients with score Z, where Z is arbitrary. A negative exponent means that the first group has a lower risk.
a The scale is defined in such a way, that measurements equal to the mean value in the population are approximately zero, while the units are
roughly equal to one SD.
Table 6. Multiple regression analysis (second round)a
Covariable Scale 6 S/sE(6) exp (6D)
Adequately controlled hypertension (H+,T+) Present = 1
Not present = 0
1.3 1,3 3.7
Insufficiently controlled hypertension (H+,T—) Present = 1
Not present = 0
3.0 2.4 19.4
Macroscopic hematuria Present = 1
Not present = 0
—1.9 —1.7 6.4-'
Microscopic hematuria (30 RBC/hpf) Present = 1
Not present = 0
1.7 2.0 5.3
Age-adjusted initial GFR (aaGFR) (aaGFR — 130)/50 with aaGFR GFR(ml/min)+
+ age (yr)
—1.6 —2.3 7.5_I
Proteinuria (Prot (g/24 hr) — 2)12 1.2 2.4 8.8
Age at biopsy (Age (yr) — 30)/10 —0.4 —1.0 2.5'
a See Table 5 legends.
As can be seen in Table 5, all these factors, except the time
factor T, seem to have some importance (according to criteria
A1 and B, see Methods), although from viewpoint A1 only the
effects of initial GFR and proteinuria are "statistically signifi-
cant" at the two-sided 5% level.
Prior to the second round, three important adjustments were
made. Firstly, patients were subdivided into three disjoint
groups with respect to hypertension: those without any hyper-
tension (H—), those with "adequately treated" hypertension
(H+,T+), and those with "insufficiently treated" hypertension
(H+ ,T—). The latter category of patients either failed to use the
drugs prescribed or had been treated for severe hypertension in
those days when the modern "triple drug regimen" (vasodila-
tors, diuretics and /3-blockers) had not been available. To apply
the proportional hazards model, the three groups with respect
to hypertension treatment were represented by two dichoto-
mous covariables (both having a score of zero in the group
without hypertension).
Secondly, it was realized that in normal control subjects there
is a gradual decline in creatinine clearance with age of about 1
mllmin clearance per annum [24]. As we are only interested in
an extra decrease of GFR due to IGAN, we decided to use the
variable "age-adjusted GFR" (aaGFR) instead of the "initial
creatinine clearance," By definition, aaGFR = GFR + age,
where GFR is measured in milliliters per minute and age in
years. Finally, the variable "time of biopsy" (T), which had
proven unimportant in the first round, was omitted. The results
of the second round are summarized in Table 6. One can see
that untreated hypertension (H+,T—) has a strong adverse
effect on kidney survival, whereas well-treated hypertension
(H+ ,T+) seems to be less harmful. Moreover, the estimated
effect of the factor "age" has lost its significance after intro-
duction of the factor "aaGFR."
In the third round of the analysis, age at biopsy and "ade-
quately treated hypertension" were dropped from the analysis
(because of criteria A and B). The other factors were retained.
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Table 7. Multiple regression analysis (third round)a
Strata
Renal
failure Lost
Cen-
sored Total Covariable Scale 6 b/sE(6)
exp
(bD) D
"No hypertension" or
"adequately con-
trolled hyperten-
sion',
9 3 58 70 Macroscopic
hematuria
Present = 1
Not present = 0
—1.7 —1.6 5.5' 1
Insufficiently con-
trolled hypertension
4 0 1 5 Microscopic hem-
aturia (>30
RBC/hpf)
Present = 1
Not present = 0
+1.9 +2.2 6.7 1
Age-adjusted initial
GFR (aaGFR)
(aaGFR — 130)/50
with aaGFR =
GFR(mllmin)+
+ age (yr)
—1.6 —2.4 7.7_I 63 mI/mm
Proteinuria (Prot (g/24 hr) — 2)/2 +1.3 +2.6 10.4 3.6 g/24 hr
a See Table 5 legends.
Patients were divided in two strata: (1) those with uncon-
trolled hypertension and (2) those with "adequately treated" or
"no hypertension." For each stratum a different baseline
cumulative hazard rate [A(tIO)] was allowed. This stratification
was performed because we wanted to have more flexibility than
that offered by the proportional hazards assumption in the
assessment of the effect of the extraordinarily strong risk factor
of untreated hypertension. To reduce the number of parame-
ters, the effects of the other covariates were assumed to be the
same for both strata. This amounts to assuming no interaction
between hypertension and the other covariates. Note that
interaction between covariates was not examined in this study.
The results of this final round are shown in Table 7 and Figure
2. The baseline cumulative hazard rate A(tO) of the five patients
with uncontrolled hypertension (broken line in Fig. 2) is only
drawn to illustrate the difference in (estimated) survival with the
other group of patients; because of its large standard errors, this
broken line should not be used for prediction. The solid line in
Figure 2 gives A(t0) for patients without uncontrolled hyper-
tension and is based on 70 patients (nine of whom eventually
were afflicted by renal failure). The vertical bars indicate
approximately 67% confidence intervals. Substitution of A(tIO),
S, and z3 in formula 1 and 3, yields an estimate of the individual
probability of survival. For practical purposes also a graphical
method based on the nomogram in Figure 2 may be useful. All
this will be explained further in the Appendix by means of a
concrete example.
According to Table 6, the individual prognosis of a patient
without uncontrolled hypertension does depend on the
presence/absence of microscopic hematuria, on the initial age-
adjusted GFR, and on the amount of proteinuria; the beneficial
effect of macroscopic hematuria seems still to be present,
though it is not statistically significant according to criterion A1.
One could wonder why the factor of macroscopic hematuria has
not been dropped from the analysis, as its estimated regression
coefficient S does not significantly differ from zero. The main
reason is that the "predictive force" of macrohematuria is large
and comparable to that of proteinuria and creatinine clearance
(criterion B).
In concrete terms, the estimated effect of the presence of
macroscopic hematuria is equivalent to (—1.71+1.3) x 2 = —2.6
g of proteinuria or (—l.7/—1.6) x 50 = + 53 mL'min age-
adjusted GFR (this follows directly from Eq. 1 and Table 7). A
favorable effect of gross hematuria is consistent with the
observation that only one out of the 34 patients with
macrohematuria had to be dialyzed (this patient had uncon-
trolled hypertension).
The addition of any of histological variables 7, 8, 9, or 14 from
Table 4 to this third model did not lead to a significant increase
of the partial likelihood function if the analysis was based on the
cases without missing observations. This means that these
histological data do not seem to carry important additional
information. However, we will have to be very cautious be-
cause histological scores are missing completely for 13 (that is,
17% of the) cases, which harbor a disproportionate amount
(46%) of renal failures. In fact, at this stage, we dare not give
any definite comment on additional influence of the histological
features on survival.
The fit of the model to the underlying data was informally
checked by estimating 5-year survival probabilities for the
patients who went into ESRD within 5 years (group A), and also
for those, who are known to have survived at least 5 years
(group B). The results are presented in Figure 3. The agreement,
as suggested by this figure, should be regarded to be too
optimistic because the fit of the model is examined on the basis
of data which were also used for constructing the model and not
on the basis of data of new patients.
Discussion
The clinical and morphological characteristics of IGAN pa-
tients we studied at the moment of renal biopsy are comparable
to those in other studies [1—3, 22, 23]. Therefore, generalization
of the results seems to be justified provided that the statistical
uncertainties are considered. Nevertheless, it is risky to extrap-
olate results obtained in our predominantly Caucasian popula-
tion to other parts of the world, especially because the defini-
tion of IGAN remains difficult, and because genetic predispo-
sition of the patients and clinical environment may differ
widely.
Fig. 2. Nomogram: estimated survival function (tJO) and estimated
cumulative hazard rate A(tIO) versus time after renal biopsy (for
standard patients with: age-adjusted GFR = 130; proteinuria = 2 g/24
hr; no macrohematuria; microhematuria <30 RBC/hpf). Symbols are:
bars, indicate 1 SE; arrows, adjustments for patients, who differ in
one or more relevant risk factors from standard patient (see Appendix);
continuous line, patients without hypertension or with well-controlled
hypertension; broken line, patients with uncontrolled hypertension. A.
Shift for each 50 mllmin age-adjusted GFR more than standard (reverse
direction of shift for each 50 mI/mm age-adjusted GFR less than
standard). B. Shift for each 2 g/24 hr proteinuria more than 2 g/24 hr
(reverse direction of shift if proteinuria less than 2 g/24 hr). C. Shift for
patients with macrohematuria (this arrow can be neglected for patients
without macrohematuria). D. Shift for patients with microhematuria 
30 RBC/hpf (neglect if microhematuria < 30 RBC/hpf). Please refer to
Figure 4.
Three different methods of survival analysis have been ap-
plied: overall actuarial survival curves, univariate analysis of
the effect of single risk factors on actuarial survival, and finally
multiple regression analysis. For the assessment of the progno-
sis of an individual patient, only the last method is relevant, as
it can determine the mutual interdependence and the relative
weights of the various risk factors. We used the proportional
hazards model as devised by Cox, which assumes that the effect
of each risk factor on the hazard rate remains constant during
the total follow-up period (see Eq. 1).
For our patients the overall survival from first manifestation
until ESRD seems to be better than that of the patients of
Hopital Necker [10]. The difference can probably be explained
by the fact that the latter study includes dialysis patients
referred for transplantation [251, while such patients are ex-
cluded in our study.
The results of our univariate analysis are similar to those
published elsewhere [7—10].
In our multiple regression analysis, survival from biopsy until
0. — __________
Fig. 3. Estimated probability of kidney survival 5 years after biopsy. A.
Patients known to have ESRD within 5 years. B. Patients known to
have functioning kidneys during at least 5 years. Symbol: t, represents
a patient dialyzed 7 years after biopsy.
ESRD is adversely influenced by five risk factors: (1) more
proteinuria; (2) more microscopic hematuria; (3) less age-
adjusted GFR; (4) uncontrolled hypertension; (5) absence of
bouts of macroscopic hematuria. We did not detect an addi-
tional influence of age, of well-treated hypertension, or of the
several morphological features. Of course, it may be possible
that such effects have been missed due to the small sample size
(age and well-treated hypertension), or, in addition, due to
missing data (in 13 patients, that is, 46% of the ESRD patients,
no morphological data were available).
It is not unexpected that the first three risk factors from the
multiple regression analysis indicate a bad prognosis: As the
microhematuria, GFR, and proteinuria were measured at least 6
weeks alter the last attack of gross hematuria, they are a
measure of the chronic "activity" of the glomerulopathy.
It is also plausible that uncontrolled hypertension has an
independent unfavorable influence on survival—even if it is not
an overt malignant hypertension. Hypertension leads to
hyperfiltration which damages the glomeruli, irrespective of
immunological disease activity [301.
However, it is very surprising that the prognosis of the
patients with the alarming symptom of macrohematuria is
estimated to be better than that for patients without gross
hematuria. In an investigation of Bennett and Kincaid-Smith
[27], for instance, macrohematuria correlated with crescents
and low GFR. It is noted in that series, biopsies and GFR
measurements were taken very early alter a bout of
A B
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macrohematuria. Moreover, it was found that crescents have an
adverse effect on kidney survival [281. In our case,
macrohematuria is not correlated with extracapilary prolifera-
tion (Pearson's r =
—0.03), negatively correlated with global
sclerosis (r =
—0.42), hypertension (r = —0.33), proteinuria (r
=
—0.29; P < 0.05), and positively with initial GFR (r = 0.32)
and microhematuria (r = 0.34). Except for the last, these
correlations are consistent with a favorable effect of
macrohematuria on survival.
In the studies of Bennett and Kincaid-Smith [27] no direct
effect of macrohematuria on kidney survival has been analyzed;
the extraordinarily high prevalence of crescents and the rela-
tively bad GFR at the moment of biopsy might be due to the
policy of biopting within a "safeguard" period of say, 6 weeks
after an attack of macrohematuria. Since the favorable influ-
ence of macrohematuria is seen in the multiple regression
analysis from biopsy to dialysis, while the effect of initial
clearance is already considered, it cannot merely be explained
by a bias due to detection of patients with visible hematuria in
an earlier stage of the disease. An alternative hypothesis is that
IGAN with macrohematuria and IGAN without macrohema-
tuna are distinct diseases with a different prognosis but with a
similar appearance on fluorescence microscopy. This view
seems to be supported by the finding, that these subentities also
differ with respect to several other parameters, including im-
munogenetics, light microscopy, age at presentation, and so
forth [6].
Presently, the only way we know to estimate the SD of A(tiO),
A(tz), and (tz), is by computer calculation [16, 20, 21, 26]. The
confidence limits for (tIz) can also be determined by an
alternative method as developed by Schaafsma and Van der
Sluis [29], which is based on discnminant analysis. This
method, however, cannot cope with censoring mechanisms and
calculations should be confined to a reduced population with a
fixed minimum period of follow-up. The relatively small number
of patients leads necessarily to rather large SD of the estimated
cumulative hazard rate and the regression coefficients 6. Nev-
ertheless, one can still think of these estimates in terms of
"very good, good, fifty-fifty, bad, and very bad."
As can be seen in Figure 3, the proportional hazards model
describes the actual behavior of our patients reasonably well.
Unfortunately, not enough patients were available to perform
such an assay of the "predictive capacity" of the model on an
independent sample.
Appendix
Question: Consider a 40-year-old hypertensive patient with a
history of macroscopic hematuria and with at the time of biopsy
a substantial microscopic hematuria (>30 RBCIhpf more than 6
weeks after the last attack), a creatinineclearance of 65 mllmin,
and 6 g of proteinuria in 24 hr. What is an appropriate estimate
of his probability of 5 years of kidney survival if the diagnosis is
IgA nephropathy and if hypertension can be controlled effec-
tively?
Using the units of Table 7 the patient's scores for the various
covariables are, respectively {+1; +1; —0.5; +2}, with coeffi-
cients {—l.7; + 1.9; —1.6; +1.3}. Substitution in Eq. 1 gives:
A(51z) = A(5to) exp (—1.7 x 1 + 1.9 x I + 1.6 x 0.5 + 1.3 x
2) = A(5O) )< e36 = A(5o) x 37.
FIg. 4. Use of nomogram for individual prognosis. Abbreviations:
(tIO), survival if age-adjusted GFR = 130, proteinuria = 2g/24 hr, no
macrohematuria, no microhematuria, no uncontrolled hypertension;
(tIz), survival if age adjusted GFR = 105, proteinuria = 6 g/24 hr,
macrohematuria present, microhematuria  30 RBC/hpf, no uncon-
trolled hypertension; a, b, C, and D: consecutive steps to obtain (tlz)
from (tIO). Also see legends to Figure 2 and the Appendix for further
explanations.
Figure 2 provides the "standard" cumulative hazard rate at 5
years after biopsy A(510) 0.04 for patients with no or adequately
treated hypertension. Therefore A(51z) = 0.04 x 37 = 1.46.
Finally, substitution in Eq. (3) gives: S(51z) = exp{—A(51z)}e1 = 0.23. Thus, the 5-year kidney survival for patients with
this particular set of scores is estimated as 23%. The same result
can be obtained by means of the noinogram of Figure 2. The
procedure is explained in Figure 4 which is an excerpt of Figure
2. By logarithmic transformation of the axes, the estimated
survival curve of a "standard"-patient (tO) can roughly be
approximated by a straight line. A "standard"-patient has an
age-adjusted GFR of 130 mllmin, a proteinuria of 2 g/24 hr, no
macrohematuria, and no substantial microhematuria (that is,
less than 30 RBC/hpf).
According to the proportional hazards model, the estimated
survival for any given patient (tIz) will be represented in this
nomogram by a straight line, running parallel to that of the
"standard" patient. The arrows a, b, C, D, indicate the shift of
the graph of (tIz) based on the scores of the given patient for
the various relevant risk factors.
The patient in our example has an aaGFR of 105 mI/mm, which
is 25 mI/mm less than that of a standard patient; adjustment for
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these differences shifts (tO) downward for 25/50 times the length
of arrow A (that is, over distance a, resulting in line I). Correction
for proteinuria is achieved by shifting line I 4/2 times arrow B
downward (over distance b, yielding line II). Likewise line III is
the result of arrow C, and the final line (tjz) for our patient can be
found via arrow D. The estimated 5-year survival probability can
be determined to be approximately 25%.
The left lower corner of Figure 2 not only contains estimates
for the regression coefficients (arrows) but also an indication of
the inaccuracy of these estimates. A bar indicates one standard
error. In the nomogram one can see, for example, that a 67%
confidence interval for the coefficient 6 of macrohematuria is
—0.63 to —2.76 (the distance between two heavy horizontal
lines corresponds with 1/4 unit of the coefficient b). Ceteris
paribus, the relative risk for a patient without macrohematuria
is therefore e063 to e276—that is, a factor 1.9 to 15.8—higher
than for someone with macrohematuria (compare Eq. 1). The
vertical bars around the survival curve (tIO) indicate the 67%
confidence intervals for patients with all scores equal to zero
(that is, for "standard" patients), as calculated by the special
FORTRAN program. The same program can be used for
estimating the standard error of S(tz) for any value of z = (z1,
..,, Zk),
For the patient in our example, the 67% confidence limits of
the point estimate (5Iz) = 23% are 5 and 50%.
Reprint requests to Dr. J. R. Beukhof, Andreas Hospital, Th. de
Bockstraat 8, 1058 NR Amsterdam, The Netherlands
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